This page shows the latest Ponesimod news and features for those working in and with pharma, biotech and healthcare.
J&J acquired the S1P receptor modulator as part its $30bn takeover of Actelion, with the FDA application based on the head-to-head phase 3 OPTIMUM study comparing ponesimod to ... Data from that trial showed that treatment with ponesimod was associated
Sets up regulatory filings and possible approval next year. Johnson &Johnson’s oral multiple sclerosis (MS) therapy ponesimod outperformed Sanofi blockbuster Aubagio in a phase 3 comparative trial, setting up regulatory ... Ponesimod, a S1P receptor
J&J also takes control of Actelion's late-stage pipeline, including multiple sclerosis candidate ponesimod and cadazolid for diarrhoeal disease, and the US group has also taken an option on
The two new drugs are predicted to bring in combined sales of $4bn-plus by 2020, and Actelion also has some pipeline candidates in which Clozel has great confidence -including ponesimod
J&J could also provide resources to bring forward Actelion's well-regarded pipeline of drugs that extends outside its core focus of PAH, including multiple sclerosis candidate ponesimod and cadazolid
More from news
Approximately 1 fully matching, plus 4 partially matching documents found.
About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...